Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities
Advanced Drug Delivery Reviews · 2026-09 · 236 · 115925
DOI: 10.1016/j.addr.2026.115925 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-09. Verfasst von Suyama Prasansali Mihindukulasooriya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia; School of Hea…. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanomedicine, Antibodies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, National Health and Medical Research Council.
Abstract (Originalsprache)
Polyethylene glycol (PEG) is widely used to improve the stability, solubility, and circulation half-life of nanoparticles, proteins, and small-molecule drugs. However, anti-PEG antibodies are increasingly recognized as a clinically relevant variable that can reshape the in vivo fate of PEGylated therapeutics, contributing to accelerated blood clearance, altered biodistribution, loss of efficacy, and, in a subset of individuals, hypersensitivity. This review integrates molecular, formulation, and host determinants of PEG immunogenicity using evidence from preclinical models and human studies. We summarize the prevalence and sources of pre-existing anti-PEG antibodies, including environmental exposure and host genetic associations, and discuss how antibody binding remodels the biomolecular corona, engages Fc- and complement-mediated pathways, and promotes phagocytic uptake that undermines PEG-mediated "stealth". We then evaluate mitigation strategies spanning polymer and lipid design, emerging PEG alternatives, and patient-centered approaches such as baseline antibody profiling and pre-treatment with free PEG in animal models. Finally, we highlight an emerging paradigm that exploits anti-PEG binding for benefit: bispecific anti-PEG antibodies and sequential pre-targeting strategies that convert PEG into a modular handle for active targeting across polymer nanoparticles, liposomes, and mRNA-lipid nanoparticles. Together, this review frames anti-PEG immunity as a central design variable in nanomedicine, linking PEG-mediated stealth, circulation time, targeting efficiency, biomolecular corona formation, and immune recognition. We propose guiding principles for deciding when PEG should be retained and optimized, replaced with alternative stealth materials, managed through patient-level screening or pre-treatment, or deliberately exploited as a modular handle for targeted delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia; School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083,…
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia.
- School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083, Australia.
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia.; Melbourne Sexual Health Centre and Department of Infectio…
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia. Electronic address: david.ju@onjcri.org.au.
Förderung
- Australian Research Council
- National Health and Medical Research Council
Zitieren
APA
Mihindukulasooriya, S. P., Wang, Z., Li, S., Saini, A., Wilson, K., Plebanski, M., Kent, S. J., & Ju, Y. (2026). Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities. Advanced Drug Delivery Reviews, 236, 115925. https://doi.org/10.1016/j.addr.2026.115925
Vancouver
Mihindukulasooriya SP, Wang Z, Li S, Saini A, Wilson K, Plebanski M, et al. Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities. Advanced Drug Delivery Reviews. 2026;236:115925. doi:10.1016/j.addr.2026.115925
BibTeX
@article{Mihindukulasooriya2026,
author = {Mihindukulasooriya, Suyama Prasansali and Wang, Zhaoran and Li, Shiyao and Saini, Anamika and Wilson, Kirsty and Plebanski, Magdalena and Kent, Stephen J and Ju, Yi},
title = {Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {236},
pages = {115925},
doi = {10.1016/j.addr.2026.115925}
}
EUVIMED